4.5 Review

The latest animal models of ovarian cancer for novel drug discovery

Journal

EXPERT OPINION ON DRUG DISCOVERY
Volume 13, Issue 3, Pages 249-257

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1080/17460441.2018.1426567

Keywords

Ovarian cancer; humanized mouse models; patient-derived xenografts; orthotopic

Funding

  1. T32 Training Program in Cancer Immunology [5T32CA207201]
  2. Claudia Adams Barr Award
  3. NATIONAL CANCER INSTITUTE [T32CA207021] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Introduction: Epithelial ovarian cancer is a heterogeneous disease classified into five subtypes, each with a different molecular profile. Most cases of ovarian cancer are diagnosed after metastasis of the primary tumor and are resistant to traditional platinum-based chemotherapeutics. Mouse models of ovarian cancer have been utilized to discern ovarian cancer tumorigenesis and the tumor's response to therapeutics. Areas covered: The authors provide a review of mouse models currently employed to understand ovarian cancer. This article focuses on advances in the development of orthotopic and patient-derived tumor xenograft (PDX) mouse models of ovarian cancer and discusses current humanized mouse models of ovarian cancer. Expert opinion: The authors suggest that humanized mouse models of ovarian cancer will provide new insight into the role of the human immune system in combating and augmenting ovarian cancer and aid in the development of novel therapeutics. Development of humanized mouse models will take advantage of the NSG and NSG-SGM3 strains of mice as well as new strains that are actively being derived.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available